Google
Trusted Resources: News & Events
Latest announcements and gatherings
SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain Crises
Results from the Phase 2 SUSTAIN clinical trial demonstrated that crizanlizumab (SEG101, Selexys Pharmaceuticals, Novartis), an anti-P-selectin antibody, reduced by 45.3% the median annual rate of sickle cell-related pain crises (SCPC), compared to placebo in patients with or without hydroxyurea therapy, a drug used to reduce the rate of painful attacks in sickle-cell disease (SCD). Crizanlizumab also significantly extended time to first and second SCPC, the researchers reported.
These results were recently presented at the ASH Annual Meeting and Exposition, and published in the New England Journal of Medicine.
+myBinderRelated Content
-
How sickled red blood cells stick to blood vesselsOne of the most common complications o...
-
Bone Marrow (Stem Cell) Transplant for Sickle Cell DiseaseBone marrow (stem cell) transplants have...
-
Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus i...ESCORT-HU (European Sickle Cell Disease ...
-
Manage Your Sickle Cell Disease Symptomshttps://www.onescdvoice.com/wp-content/u...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
SCDAA Gene Therapy Town Hall – Webinarhttps://www.youtube.com/watch?v=J77Gq9yI...
-
Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.